Transplant outcomes by DRB1 antigen
Outcome . | DR15-, no. (%) . | DR15+, no. (%) . | P . |
|---|---|---|---|
| No. patients | 132 | 35 | |
| Acute GVHD grades II to IV | 55 (42) | 8 (23) | .041 |
| Chronic GVHD | NS | ||
| NE | 46 (35) | 9 (26) | |
| Limited/none | 43 (33) | 10 (29) | |
| Extensive | 43 (33) | 16 (46) | |
| Chronic GVHD severity | NS | ||
| NE | 46 (35) | 9 (26) | |
| None/mild | 52 (39) | 15 (43) | |
| Moderate/severe | 34 (26) | 11 (31) | |
| Disease status after BMT | NS | ||
| Continuous CR | 108 (82) | 25 (71) | |
| Relapse/progression | 24 (18) | 10 (29) | |
| Overall survival | NS | ||
| Alive | 53 (40) | 14 (40) | |
| Dead | 79 (60) | 21 (60) | |
| Primary cause of death | NS | ||
| Disease | 19 (14) | 6 (17) | |
| GVHD | 19 (14) | 4 (11) | |
| Infection | 20 (15) | 4 (11) | |
| Toxicity | 14 (11) | 5 (14) | |
| Hemorrhage | 3 (2) | 2 (6) | |
| Other | 4 (3) | 0 | |
| Alive | 53 (40) | 14 (40) | |
| Median follow-up, mo (range) | 58 (1-129) | 54 (1-129) | NS |
Outcome . | DR15-, no. (%) . | DR15+, no. (%) . | P . |
|---|---|---|---|
| No. patients | 132 | 35 | |
| Acute GVHD grades II to IV | 55 (42) | 8 (23) | .041 |
| Chronic GVHD | NS | ||
| NE | 46 (35) | 9 (26) | |
| Limited/none | 43 (33) | 10 (29) | |
| Extensive | 43 (33) | 16 (46) | |
| Chronic GVHD severity | NS | ||
| NE | 46 (35) | 9 (26) | |
| None/mild | 52 (39) | 15 (43) | |
| Moderate/severe | 34 (26) | 11 (31) | |
| Disease status after BMT | NS | ||
| Continuous CR | 108 (82) | 25 (71) | |
| Relapse/progression | 24 (18) | 10 (29) | |
| Overall survival | NS | ||
| Alive | 53 (40) | 14 (40) | |
| Dead | 79 (60) | 21 (60) | |
| Primary cause of death | NS | ||
| Disease | 19 (14) | 6 (17) | |
| GVHD | 19 (14) | 4 (11) | |
| Infection | 20 (15) | 4 (11) | |
| Toxicity | 14 (11) | 5 (14) | |
| Hemorrhage | 3 (2) | 2 (6) | |
| Other | 4 (3) | 0 | |
| Alive | 53 (40) | 14 (40) | |
| Median follow-up, mo (range) | 58 (1-129) | 54 (1-129) | NS |
DR15- indicates no alleles for 15 at DRB1; DR15+, 1 or 2 alleles for 15 at DRB1; GVHD, graft-versus-host disease; NS, not significant (P > .1); NE, not evaluable, died before day + 100 after BMT; and CR, complete remission.